Literature DB >> 2311173

Pharmacokinetics of reduced folates after short-term infusion of d, 1-folinic acid.

A Schalhorn1, M Kühl, G Stupp-Poutot, V Nüssler.   

Abstract

After the use of d,1-folinic acid (d,1-CHO-THF), pharmacokinetic measurements should take into account 1-CHO-THF and its metabolite 1-methyltetrahydrofolic acid (1-CH3-THF) as well as d-CHO-THF. For this purpose, we developed a simple and rapid assay by combining reversed-phase HPLC to determine total levels of d,1-CHO-THF and CH3-THF and chiral HPLC to separate the biologically active 1-CHO-THF from the inactive d-CHO-THF. We investigated the pharmacokinetics after short-term infusion of 300 mg d,1-CHO-THF in ten healthy volunteers. With a mean of 56.5 min, 1-CHO-THF exhibits a rapid body clearance of 222 ml/min, about 60% of which is caused by metabolism to CH3-THF and 40%, by renal excretion. CH3-THF has a terminal half-life of 208 min and a total body clearance of 88.9 ml/min, which is essentially the same as the renal clearance. Due to the lower clearance of CH3-THF, its AUC (2,132 microM x min) exceeds that of 1-CHO-THF (1445 microM x min) by approximately 50%. In contrast to that of the reduced 1-folates, the total body and renal clearance of d-CHO-THF is very low, with values of 13.2 and 12.9 ml/min, respectively. This results in a very high AUC of 24, 269 microM x min, which is higher by factors of 17 and 11 than those of 1-CHO-THF and CH3-THF, respectively. The implications of the distinct kinetics of the reduced 1-folates and d-CHO-THF for the efficacy of folinic acid/5-fluorouracil therapy and adequate protocols for the treatment of advanced colorectal cancer are discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2311173     DOI: 10.1007/bf00686056

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  15 in total

1.  Assay for citrovorum factor (NSC-3590) in the presence of methotrexate (NSC-740).

Authors:  B M Mehta; D J Hutchison
Journal:  Cancer Chemother Rep       Date:  1975 Sep-Oct

2.  A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma.

Authors:  N Petrelli; L Herrera; Y Rustum; P Burke; P Creaven; J Stulc; L J Emrich; A Mittelman
Journal:  J Clin Oncol       Date:  1987-10       Impact factor: 44.544

3.  Clinical pharmacology of the stereoisomers of leucovorin during repeated oral dosing.

Authors:  R L Schilsky; K E Choi; E E Vokes; A Guaspari; C Guarnieri; S Whaling; M A Liebner
Journal:  Cancer       Date:  1989-03-15       Impact factor: 6.860

4.  Direct resolution of the stereoisomers of leucovorin and 5-methyltetrahydrofolate using a bovine serum albumin high-performance liquid chromatographic chiral stationary phase coupled to an achiral phenyl column.

Authors:  I W Wainer; R M Stiffin
Journal:  J Chromatogr       Date:  1988-01-22

5.  Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil.

Authors:  R M Evans; J D Laskin; M T Hakala
Journal:  Cancer Res       Date:  1981-09       Impact factor: 12.701

6.  Pharmacokinetic analysis of (6S)-5-formyltetrahydrofolate (1-CF), (6R)-5-formyltetrahydrofolate (d-CF) and 5-methyltetrahydrofolate (5-CH3-THF) in patients receiving constant i.v. infusion of high-dose (6R,S)-5-formyltetrahydrofolate (leucovorin).

Authors:  J A Straw; E M Newman
Journal:  Adv Exp Med Biol       Date:  1988       Impact factor: 2.622

7.  Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.

Authors:  D Machover; E Goldschmidt; P Chollet; G Metzger; J Zittoun; J Marquet; J M Vandenbulcke; J L Misset; L Schwarzenberg; J B Fourtillan
Journal:  J Clin Oncol       Date:  1986-05       Impact factor: 44.544

8.  Pharmacokinetics of leucovorin (D,L-5-formyltetrahydrofolate) after intravenous injection and constant intravenous infusion.

Authors:  J A Straw; E M Newman; J H Doroshow
Journal:  NCI Monogr       Date:  1987

9.  Plasma kinetic study of folinic acid and 5-methyltetrahydrofolate in healthy volunteers and cancer patients by high-performance liquid chromatography.

Authors:  B Payet; G Fabre; N Tubiana; J P Cano
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

10.  Leucovorin plus 5-fluorouracil: an effective treatment for metastatic colon cancer.

Authors:  L R Laufman; K A Krzeczowski; R Roach; M Segal
Journal:  J Clin Oncol       Date:  1987-09       Impact factor: 44.544

View more
  4 in total

1.  Tolerability and pharmacokinetics of disodium folinate following single intravenous doses in healthy Chinese subjects: an open-label, randomized, single-center study.

Authors:  Yani Liu; Jiali Zhou; Zhongfang Li; Chunxiao Yang; Jianhong Wu; Yu Zhang; Shaojun Shi; Yunqiao Li
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-08-31       Impact factor: 2.441

2.  Disposition of 5-formyl- and 5-methyltetrahydrofolic acid in serum after i.v. bolus of calcium folinate: pharmacokinetic drug interaction with preadministered interferon-alpha-2b.

Authors:  M J Czejka; J Schüller; C Weiss; S Bandak; B Meyer; D Simon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Oct-Dec       Impact factor: 2.441

3.  Stereospecific pharmacokinetics of rac-5-methyltetrahydrofolic acid in patients with advanced colorectal cancer.

Authors:  R M Mader; G G Steger; B Rizovski; M P Djavanmard; W Scheithauer; R Jakesz; H Rainer
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335

4.  The pharmacokinetics of reduced folates after intraperitoneal and intravenous administration of racemic [6S,R]-folinic acid.

Authors:  J H Sips; O van Tellingen; W J Nooijen; S Rodenhuis; W J Ten Bokkel Huinink; J H Beijnen
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.